CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who ...
Phase 2
San Francisco, California, United States and 25 other locations
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple...
Phase 1
San Francisco, California, United States and 9 other locations
CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...
Phase 2
Palo Alto, California, United States and 35 other locations
The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant...
Phase 2
San Francisco, California, United States and 9 other locations
versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...
Phase 3
Palo Alto, California, United States and 59 other locations
1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple...
Phase 1, Phase 2
San Francisco, California, United States and 12 other locations
This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants wi ...
Phase 1
Palo Alto, California, United States and 8 other locations
This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bisp...
Phase 1, Phase 2
San Francisco, California, United States and 13 other locations
versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...
Phase 3
San Francisco, California, United States and 126 other locations
The purpose of this study is to evaluate the effectiveness and safety of BMS-986393 in participants with relapsed or refractory multiple myeloma...
Phase 2
San Francisco, California, United States and 46 other locations
Clinical trials
Research sites
Resources
Legal